AMP® Symposium Day 1: Autoimmune and Immune-Mediated Diseases

The Accelerating Medicines Partnership® (AMP®) Program Autoimmune and Immune-Mediated Diseases (AMP AIM) is a precompetitive partnership that brings together the resources of 20 partner organizations spanning the public, private, and not-for-profit sectors. Managed by the FNIH, the project builds on the success of AMP RA/SLE, which pioneered a transformational approach to dissect how these diseases occur at the individual cell level. AMP RA/SLE advanced new technologies and analytical methods using biopsy and blood samples of diseased tissue from major organs, such as the kidney in lupus and the joints in arthritis. As a result, novel cell populations and pathways have been discovered, suggesting promising new targets for drug development.

The Accelerating Medicines Partnership® (AMP®) Program was launched in February 2014 to bring together the resources and expertise of both the National Institutes of Health (NIH) and the private sector to solve pressing challenges in various diseases and disease areas. The AMP program, managed by the FNIH, is comprised of projects with a common goal of accelerating the process of bringing new and effective therapies to patients and operates under the broad principle of delivering pre-competitive advancements to the research and medical fields to enable broad access and use of AMP research discoveries. Originally focused on three specific diseases, the program has since grown to 10 individual projects representing the contributions and participation of 16 NIH institutes and over 70 private sector partners.

This inaugural scientific symposium celebrated the 10th anniversary of the program, highlighted successful innovation and collaboration in each of the individual AMP project areas, and provided a forum for discussions and cross-collaboration in the broader AMP research community.